01P Stock Overview
Provides clinical research-based drug and medical device development services in North America, Europe, and Asia. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 6/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 01P from our risk checks.
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
Medpace Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$313.40 |
| 52 Week High | US$418.70 |
| 52 Week Low | US$286.00 |
| Beta | 1.36 |
| 1 Month Change | -4.63% |
| 3 Month Change | -2.49% |
| 1 Year Change | -15.53% |
| 3 Year Change | 128.76% |
| 5 Year Change | 270.89% |
| Change since IPO | 1,110.79% |
Recent News & Updates
Recent updates
Shareholder Returns
| 01P | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | -3.5% | -2.4% | 0.9% |
| 1Y | -15.5% | -9.7% | 14.4% |
Return vs Industry: 01P underperformed the German Life Sciences industry which returned -9.1% over the past year.
Return vs Market: 01P underperformed the German Market which returned 15.1% over the past year.
Price Volatility
| 01P volatility | |
|---|---|
| 01P Average Weekly Movement | 4.4% |
| Life Sciences Industry Average Movement | 6.3% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.6% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: 01P has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 01P's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 5,900 | August Troendle | www.medpace.com |
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.
Medpace Holdings, Inc. Fundamentals Summary
| 01P fundamental statistics | |
|---|---|
| Market cap | €9.58b |
| Earnings (TTM) | €389.87m |
| Revenue (TTM) | €2.03b |
24.7x
P/E Ratio4.7x
P/S RatioIs 01P overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 01P income statement (TTM) | |
|---|---|
| Revenue | US$2.11b |
| Cost of Revenue | US$682.10m |
| Gross Profit | US$1.43b |
| Other Expenses | US$1.02b |
| Earnings | US$404.34m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 13.27 |
| Gross Margin | 67.66% |
| Net Profit Margin | 19.17% |
| Debt/Equity Ratio | 0% |
How did 01P perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/28 11:20 |
| End of Day Share Price | 2025/02/28 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Medpace Holdings, Inc. is covered by 19 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Eric Coldwell | Baird |
| Ishan Majumdar | Baptista Research |
| Erin Wilson Wright | Credit Suisse |